The outlook for the stock of Natco Pharma is turning bearish. The stock fell 2 per cent on Monday to decisively close below the 200-DMA at ₹487. The stock was in a strong uptrend from the March low of ₹390. The 100-DMA at ₹497 halted this rally last week. The stock tested the psychological resistance at ₹500 twice last week but failed to break above it. The subsequent reversal in the last two trading days has increased the possibility of seeing a corrective fall in the near term.
The 200-DMA may now act as a good resistance. While below it, the stock can fall to ₹458 — the 38.2 per cent Fibonacci retracement support or ₹451 — the 21-DMA level. Traders with a short-term perspective can go short. Stop-loss can be kept at ₹489 for a target of ₹460. Revise the stop-loss lower to ₹472 as the stock declines to ₹465. The outlook for this stock will turn bullish only if it breaks decisively above the 100-DMA resistance.
(Note: The recommendations are based on technical analysis. There is a risk of loss in trading.)
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.